Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease.

Abstract excerpt

INTRODUCTION: Cholinergic dysfunction, demonstrated in the late 1970s and early 1980s, led to the introduction of acetylcholinesterase inhibitors (AChEIs) in 1993 (Tacrine) to enhance cholinergic neurotransmission as the first line of treatment against Alzheimer's disease (AD). The new generation of AChEIs, represented by Donepezil (1996), Galantamine (2001) and Rivastigmine (2002), is the only treatment for AD...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Alzheimer Disease
• Share to Apolipoproteins E
• Share to Cholinesterase Inhibitors